Engels Eric A, Mandal Soutrik, Corley Douglas A, Blosser Christopher D, Hart Allyson, Lynch Charles F, Qiao Baozhen, Pawlish Karen S, Haber Gregory, Yu Kelly J, Pfeiffer Ruth M
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA; Department of Population Health, New York University, New York, New York, USA.
Am J Transplant. 2025 Mar;25(3):545-555. doi: 10.1016/j.ajt.2024.08.018. Epub 2024 Sep 5.
A previous cancer diagnosis can preclude patients from consideration for solid organ transplantation. Statistical models may improve candidate selection. We fitted statistical cure models and estimated 5-year cancer-specific survival (5yCSS) for colorectal cancer patients in the United States using registry data. The median cure probability at cancer diagnosis for patients in the general population was 0.67. Among 956 colorectal cancer patients who underwent solid organ transplantation, the median time since diagnosis was 6.3 years and the median 5yCSS at transplantation was 0.96. Patients with a 5yCSS below 0.90 had increased posttransplant cancer-specific mortality (hazard ratio 3.31, 95% CI 1.52-7.21). Compared with recently published guidelines, our models suggested shorter wait times for some groups of colorectal cancer patients (eg, stage IIA cancers) and longer wait times for others (stages IIB, IIIB, IIIC, IV). In conclusion, colorectal cancer patients undergoing solid organ transplantation had excellent prognoses, reflecting selection incorporating existing guidelines and clinical judgment. Nonetheless, 5yCSS probabilities estimated from cure models offer additional prognostic information for patients considered for transplantation and identify situations where current guidelines might be revised. We developed a web-based tool for clinicians to calculate 5yCSS probabilities for use in transplant evaluation for individual colorectal cancer patients (https://dceg.cancer.gov/tools/risk-assessment/calculator-of-colorectal-cancer-survival-probability).
既往癌症诊断可能会使患者失去接受实体器官移植的机会。统计模型或许能改善候选者的选择。我们利用登记数据拟合了统计治愈模型,并估算了美国结直肠癌患者的5年癌症特异性生存率(5yCSS)。普通人群中患者在癌症诊断时的治愈概率中位数为0.67。在956例接受实体器官移植的结直肠癌患者中,自诊断以来的时间中位数为6.3年,移植时的5yCSS中位数为0.96。5yCSS低于0.90的患者移植后癌症特异性死亡率增加(风险比3.31,95%置信区间1.52 - 7.21)。与最近发布的指南相比,我们的模型显示某些结直肠癌患者组(如IIA期癌症)的等待时间较短,而其他组(IIB期、IIIB期、IIIC期、IV期)的等待时间较长。总之,接受实体器官移植的结直肠癌患者预后良好,这反映了结合现有指南和临床判断的筛选情况。尽管如此,从治愈模型估算的5yCSS概率为考虑移植的患者提供了额外的预后信息,并识别出可能需要修订当前指南的情况。我们为临床医生开发了一个基于网络的工具,用于计算5yCSS概率,以用于个体结直肠癌患者的移植评估(https://dceg.cancer.gov/tools/risk-assessment/calculator-of-colorectal-cancer-survival-probability)。